RecruitingNot ApplicableNCT03203239

Red Light Treatment in Peripheral Artery Disease

Vasodilatory Effects of Light on Peripheral Artery Disease


Sponsor

University of Alabama at Birmingham

Enrollment

40 participants

Start Date

Jan 17, 2018

Study Type

INTERVENTIONAL

Conditions

Summary

Subjects with a known diagnosis of peripheral artery disease as measured by an abnormal ankle brachial index (\<.9 or \>1.1) will undergo a single 5 min exposure of 670 nm light, 1 cm above the gastrocnemius muscle. Blood flow will be measured by infusion of ultrasound contrast and subsequent acquisition of ultrasound images. 2 blood samples will be collected for measurement of nitric oxide metabolites.


Eligibility

Min Age: 18 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Octafluoropropane and a medical device called Red Light (670 nm energy) for people with claudication, intermittent, peripheral artery disease, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 85 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICERed Light (670 nm energy)

Light Emitting Diode light source (670 nm wavelength with output up to 75mW/cm2) will be placed over the gastrocnemius muscle. The light will be on for 5 minutes.

DRUGOctafluoropropane

All subjects will undergo infusion of octafluoropropane to measure peripheral blood flow.


Locations(1)

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03203239


Related Trials